Last mentioned: Mar 24, 2026
Commercial Target
Anticipated focus on commercial scaling and market penetration for DeepView AI.
FY 2025 Earnings Release
Company reports $19.7M in total R&D revenue for the full year.
2026 Guidance Introduced
Management provides first-ever revenue guidance for the upcoming fiscal year.
Earnings Release
Official announcement of Q4 and FY2025 results and introduction of 2026 guidance.
Q4 Earnings Release
Spectral AI reports Q4 revenue beat and introduces 2026 revenue guidance.
BARDA Award
Company receives $31.7 million in non-dilutive funding for the DeepView System.
Guidance Period Start
Commencement of the 2026 fiscal year covered by the new revenue outlook.
Year-End Cash Position
Spectral AI closes the year with $15.4 million in cash and equivalents.
Fiscal Year End
Spectral AI closes the year with $15.4M in cash and $19.7M in R&D revenue.
Fiscal Year End
Spectral AI closes FY2025 with $19.7M in R&D revenue and $15.4M in cash.
Spectral AI reported a significant Q4 2025 earnings beat with revenue of $3.8 million and a surprise GAAP profit, bolstered by a recent $31.7 million BARDA award. The company has introduced its first revenue guidance for 2026, marking a critical transition from R&D to commercial-scale medical AI diagnostics.
Spectral AI, Inc. closed fiscal year 2025 with $19.7 million in research and development revenue and a robust $15.4 million cash balance. The company is now transitioning toward a commercial model, supported by newly introduced revenue guidance for the 2026 fiscal year.
Spectral AI reported full-year 2025 R&D revenue of $19.7 million, driven by its DeepView AI-driven wound diagnostic platform. The company ended the year with $15.4 million in cash and provided its first revenue outlook for 2026, signaling a transition toward commercial scale.
Spectral AI reported full-year 2025 research and development revenue of $19.7 million, driven by its DeepView AI platform. With a strengthened cash position of $15.4 million, the company has introduced its first revenue guidance for 2026 as it transitions toward commercialization.
Spectral AI has been awarded $31.7 million in non-dilutive funding from BARDA to accelerate the development and clinical validation of its DeepView® System. This investment aims to enhance AI-driven medical diagnostics for faster, more accurate wound care decisions, particularly in burn and diabetic foot ulcer management.